Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
KEYNOTE-199 trial: what clinicians have said so far
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
- NCT02787005 ↗
- Completed
- Merck Sharp & Dohme LLC
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on KEYNOTE-199 (pembrolizumab; pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-199 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 2 podcast episodes, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Pembrolizumab
- Arms
- Cohort 1: PD-L1 positive with measurable disease · Experimental
- Cohort 2: PD-L1 negative with measurable disease · Experimental
- Cohort 3: Bone metastases with non-measurable disease · Experimental
- Cohort 4: RECIST 1.1-measureable disease · Experimental
- Cohort 5: Bone metastases only or bone-predominant disease · Experimental
- Enrollment
- 388
- Primary outcomes
- Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort 1, Cohort 2, Cohort 4 and Cohorts 1 and 2 Combined)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jul 1, 2016
- Primary completion
- Feb 28, 2022
- Results posted
- Yes
- Registry record
- NCT02787005 · updated Nov 21, 2024
Publications
linked from the registry- Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27. PubMed 31774688
- Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):411-418. doi: 10.1038/s41391-024-00865-5. Epub 2024 Aug 12. PubMed 39134652
- Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, Lang L, Jin F, Rubin EH, Snyder A, Lunceford J. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022 Jan;10(1):e003091. doi: 10.1136/jitc-2021-003091. PubMed 35101941